Biomarkers and translational research and precision medicine

15P - Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials

Authors
  • Paul Jank (Marburg, Germany)
  • Sibylle Loibl (Neu-Isenburg, Germany)
  • Peter A. Fasching (Erlangen, Germany)
  • Thomas Karn (Frankfurt am Main, Germany)
  • Frederik Marmé (Heidelberg, Germany)
  • Volkmar Mueller (Hamburg, Germany)
  • Christian Schem (Hamburg, Germany)
  • Elmar Stickeler (Aachen, Germany)
  • Bianca Lederer (Neu-Isenburg, Germany)
  • Carsten Denkert (Marburg, Germany)
Speakers
  • Paul Jank (Marburg, Germany)

Previous ePoster
14P - Outcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience

Next ePosters
16P - Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
17P - Are single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study
18P - Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target
19P - The clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay
20P - ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)
25P - Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)
30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
33P - Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm
34P - Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 159 breast cancer patients - indicating tumoral heterogeneity
35P - Downregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer: A new insight into the mechanism of induction of antitumor immunity